Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT ID: NCT01189032
Last Updated: 2014-08-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
320 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01101984
Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
NCT01240382
Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease
NCT03216096
A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes
NCT01890941
Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease
NCT01239069
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High concentration
DE-089 ophthalmic solution
Low concentration
DE-089 ophthalmic solution
Placebo
Placebo ophthalmic solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DE-089 ophthalmic solution
DE-089 ophthalmic solution
Placebo ophthalmic solution
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Keratoconjunctival disorder confirmed with vital dye staining
* Abnormal Schirmer score results
Exclusion Criteria
* Those who need to wear contact lenses during the clinical study
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Santen Pharmaceutical Co., Ltd.
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santen study sites
Osaka, Osaka, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00890404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.